Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BPTF | Q12830 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22581718 | 0.86 | DEGS1 (0.55) | KMT2AGPR119DRD2DRD4PANK3 | |
| SCHEMBL30567210 | 0.86 | DEGS1 (0.55) | KMT2AGPR119DRD2DRD4PANK3 | |
| SCHEMBL26758702 | 0.86 | KMT2A (0.48) | KMT2AMEN1GPR119GAASMN1; SMN2 | |
| SCHEMBL26758684 | 0.82 | GPR119 (0.48) | KMT2AMEN1GPR119SMOCNR2 | |
| SCHEMBL30567093 | 0.80 | GPR119 (0.39) | KMT2AGPR119GAASMN1; SMN2DRD2 | |
| SCHEMBL22581675 | 0.80 | GPR119 (0.39) | KMT2AGPR119GAASMN1; SMN2DRD2 | |
| SCHEMBL26758709 | 0.80 | KMT2A (0.51) | KMT2AMEN1GPR119GAAKDM4E | |
| SCHEMBL12645428 | 0.79 | PHGDH (0.46) | KMT2AMEN1GPR119GAASMN1; SMN2 | |
| SCHEMBL26758692 | 0.78 | KMT2A (0.45) | KMT2AMEN1GAADRD2DEGS1 | |
| SCHEMBL14581791 | 0.77 | DHFR (0.44) | KMT2AMEN1GPR119GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | KMT2A 3939/4885MEN1 1628/4885GPR119 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.